Dawnrays Pharmaceutical Holdings Ltd.

As of December 31, 2025, Dawnrays Pharmaceutical Holdings Ltd. carries a market capitalization of 1.83B, placing it among publicly traded companies globally. Its enterprise value stands at 165.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Dawnrays Pharmaceutical Holdings Ltd.'s next confirmed earnings release is scheduled for March 19, 2027.

As of December 31, 2025, Dawnrays Pharmaceutical Holdings Ltd. has 1.50B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Dawnrays Pharmaceutical Holdings Ltd. maintains a current ratio of 4.64, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Dawnrays Pharmaceutical Holdings Ltd.'s stock has declined approximately 18.10% over the past 52 weeks. The 50-day moving average sits at 0.98, while the 200-day moving average is 1.09.

As of December 31, 2025, Dawnrays Pharmaceutical Holdings Ltd. holds 1.75B in cash and equivalents against 86.22M in total debt, resulting in a net debt position of -1.21B. Total book value stands at 3.77B, with working capital of 2.00B providing operational flexibility.

Dawnrays Pharmaceutical Holdings Ltd.'s most recent stock split took place on August 20, 2018 with a 1:2 split ratio.